Literature DB >> 26286068

Familial hematological malignancies: ASXL1 gene investigation.

W S Hamadou1, R E Abed2, S Besbes2, V Bourdon3, A Fabre3, Y B Youssef2,4, M A Laatiri5, F Eisinger6, V Mari7, P Gesta8, H Dreyfus9, V Bonadona10, C Dugast11, H Zattara12, L Faivre13, S Y Jemni14, T Noguchi3, A Khélif2,4, H Sobol3, Z Soua2.   

Abstract

PURPOSE: Familial aggregation among patients with several hematological malignancies has been revealed. This emphasizes the importance of genetic factors. Only few genes predisposing to familial hematological malignancies have been reported until now due to the low occurrence. We have described in previous study PRF1 and CEBPA variants that might contribute to the background of genetic factors, which encourage us to extend our investigations to other cooperating genes. The aim of this study is to determine whether germline additional sex combs-like 1 (ASXL1) gene mutations may be involved? METHODS/PATIENTS: In this study, we investigated the candidate gene ASXL1 by direct sequencing in 88 unrelated Tunisian and French families with aggregated hematological malignancies.
RESULTS: We report a new p.Arg402Gln germline missense substitution in two related Tunisian patients which has not been previously described. We identified here this variant for the first time in non-Hodgkin lymphoma. The p.Arg402Gln variant was not found in 200 control chromosomes. In silico analysis has predicted potential deleterious effect on ASXL1 protein.
CONCLUSIONS: From an extended candidate genes analyzed in the field of familial hematological malignancies, ASXL1 might be involved. This variant should be considered since a potential damaging effect was predicted by in silico analysis, with a view to develop functional assay in order to investigate the biological assessment.

Entities:  

Keywords:  ASXL1 gene; Familial hematological malignancies; Germline mutation; Non-Hodgkin lymphoma

Mesh:

Substances:

Year:  2015        PMID: 26286068     DOI: 10.1007/s12094-015-1379-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  29 in total

Review 1.  Polycomb silencing mechanisms and the management of genomic programmes.

Authors:  Yuri B Schwartz; Vincenzo Pirrotta
Journal:  Nat Rev Genet       Date:  2007-01       Impact factor: 53.242

2.  Mutations of ASXL1 gene in myeloproliferative neoplasms.

Authors:  N Carbuccia; A Murati; V Trouplin; M Brecqueville; J Adélaïde; J Rey; W Vainchenker; O A Bernard; M Chaffanet; N Vey; D Birnbaum; M J Mozziconacci
Journal:  Leukemia       Date:  2009-07-16       Impact factor: 11.528

3.  De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome.

Authors:  Alexander Hoischen; Bregje W M van Bon; Benjamín Rodríguez-Santiago; Christian Gilissen; Lisenka E L M Vissers; Petra de Vries; Irene Janssen; Bart van Lier; Rob Hastings; Sarah F Smithson; Ruth Newbury-Ecob; Susanne Kjaergaard; Judith Goodship; Ruth McGowan; Deborah Bartholdi; Anita Rauch; Maarit Peippo; Jan M Cobben; Dagmar Wieczorek; Gabriele Gillessen-Kaesbach; Joris A Veltman; Han G Brunner; Bert B B A de Vries
Journal:  Nat Genet       Date:  2011-06-26       Impact factor: 38.330

4.  Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.

Authors:  Marta Pratcorona; Saman Abbas; Mathijs A Sanders; Jasper E Koenders; François G Kavelaars; Claudia A J Erpelinck-Verschueren; Annelieke Zeilemakers; Bob Löwenberg; Peter J M Valk
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

5.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.

Authors:  S V Tavtigian; A M Deffenbaugh; L Yin; T Judkins; T Scholl; P B Samollow; D de Silva; A Zharkikh; A Thomas
Journal:  J Med Genet       Date:  2005-07-13       Impact factor: 6.318

6.  Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor.

Authors:  Yang-Sook Cho; Eun-Joo Kim; Ui-Hyun Park; Hong-Sig Sin; Soo-Jong Um
Journal:  J Biol Chem       Date:  2006-04-10       Impact factor: 5.157

7.  Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Julien Bonansea; Nathalie Cervera; Nadine Carbuccia; Arnaud Lagarde; Thomas Prebet; Meyer Nezri; Danielle Sainty; Sylviane Olschwang; Luc Xerri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2009-04-15       Impact factor: 6.998

8.  Molecular study of CEBPA in familial hematological malignancies.

Authors:  R El Abed; V Bourdon; L Huiart; F Eisinger; A Khelif; M Frenay; P Gesta; L Demange; H Dreyfus; V Bonadona; C Dugast; H Zattara; L Faivre; T Noguchi; R Sauvan; Z Soua; H Sobol
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

Review 9.  Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Authors:  Véronique Gelsi-Boyer; Mandy Brecqueville; Raynier Devillier; Anne Murati; Marie-Joelle Mozziconacci; Daniel Birnbaum
Journal:  J Hematol Oncol       Date:  2012-03-21       Impact factor: 17.388

Review 10.  Functional and cancer genomics of ASXL family members.

Authors:  M Katoh
Journal:  Br J Cancer       Date:  2013-06-04       Impact factor: 7.640

View more
  4 in total

Review 1.  Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk.

Authors:  Jenna A Fernandez; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2022-06-02       Impact factor: 4.213

2.  Case Report: Heterozygous Germline Variant in EIF6 Additional to Biallelic SBDS Pathogenic Variants in a Patient With Ribosomopathy Shwachman-Diamond Syndrome.

Authors:  Ibrahim Taha; Selena Foroni; Roberto Valli; Annalisa Frattini; Pamela Roccia; Giovanni Porta; Marco Zecca; Elena Bergami; Marco Cipolli; Francesco Pasquali; Cesare Danesino; Claudia Scotti; Antonella Minelli
Journal:  Front Genet       Date:  2022-08-12       Impact factor: 4.772

3.  Acute myeloid leukemia in a father and son with a germline mutation of ASXL1.

Authors:  Karen Seiter; Kyaw Htun; Paul Baskind; Zach Liu
Journal:  Biomark Res       Date:  2018-02-13

4.  Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition.

Authors:  Cristina Andrés-Zayas; Julia Suárez-González; Gabriela Rodríguez-Macías; Nieves Dorado; Santiago Osorio; Patricia Font; Diego Carbonell; María Chicano; Paula Muñiz; Mariana Bastos; Mi Kwon; José Luis Díez-Martín; Ismael Buño; Carolina Martínez-Laperche
Journal:  Mol Oncol       Date:  2021-07-16       Impact factor: 6.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.